Compare AbCellera Biologics Inc (ABCL) vs Alibaba Group (BABA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Alibaba Group — how do they compare? AbCellera Biologics Inc trades at $9.24 (market cap $2.85B), while Alibaba Group trades at $124.91 (market cap $309.65B). The key difference: Alibaba Group is far larger — about 108.6× AbCellera Biologics Inc's market cap, and Alibaba Group pays a 0.79% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | BABA | |
|---|---|---|
Market Cap | $2.85B | $309.65B |
Sector | Health | Consumer Cyclical |
52-Week High | $9.76 | $189.34 |
52-Week Low | $2.78 | $94.83 |
Enterprise Value | $2.45B | $304.43B |
Volume | — | 18,069,938 |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
Alibaba (BABA) trades at $128.41, up 1.26% today, with a bullish technical signal and strong analyst support. Recent earnings misses contrast with solid fundamentals: revenue grew to $996.35B in 2025, net income margin expanded to 13.05%, and valuation ratios like P/E of 19.7 appear reasonable. The company announced a $1.05 dividend for H1-26 and faces multiple class-action lawsuits filed in August 2026, alleging securities fraud between June 2025 and June 2026.
Outlook is mixed: bullish analyst consensus (86% buy ratings) and a $195 price target suggest upside, but legal risks and earnings volatility pose headwinds. Investment opportunity hinges on AI growth and cloud strength, while risks include litigation outcomes and competitive pressures in China.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Alibaba Group
Alibaba Group Holding Limited operates as a holding company. The Company provides internet infrastructure, electronic commerce, online financial, and internet content services through its subsidiaries. Alibaba Group Holding offers its products and services worldwide.
Read more on BABA →
